Most Recent
A barrister who represented her sons in court after being refused a practicing certificate by the Victorian Bar has lost an appeal, with a tribunal disqualifying her from seeking a practicing certificate for four years.
The plaintiff in an unsuccessful class action against Bayer over its Essure contraceptive device wants to see whether she can avoid paying costs in the case before deciding on whether to appeal the loss.
Medical device maker Bayer has successfully defended a class action over its Essure contraceptive, with a judge finding the evidence fell short of proving the device caused chronic inflammation.
A Victorian barrister found guilty of contempt for representing her sons despite an order barring her from practicing can't re-open reviews of two decisions denying her a certificate.
A judge has hit Airbnb with a $15 million penalty for misleading Australian consumers by displaying accommodation prices in US dollars, on top a $15 million consumer redress scheme the vacation rental giant has implemented.
The consumer watchdog has asked a court to impose a $15 million penalty against Airbnb in addition to a $15 million consumer redress scheme, in a case alleging the vacation rental giant misled Australian consumers by displaying prices in US dollars.
Bayer told a jury that clinical trials from the 1990’s to 2014 showed its Essure birth control device was “safe and efficacious”, as the pharmaceutical giant faces trial in a class action by patients who claim they suffered debilitating injuries from the device.
Pharmaceutical giant Bayer cannot write off debilitating chronic pain and bleeding which patients allegedly experienced after being implanted with Essure contraceptives as “common women's symptoms”, a court has heard in the first day of trial in a long-running class action.
A class action against Bayer over its Essure contraceptive has lost a bid to knock out the pharmaceutical giant’s defence that argues any defects in the device could not have been discovered given the state of scientific knowledge at the time the implants were sold in Australia.
A court has found National Australia Bank engaged in unconscionable conduct in knowingly overcharging thousands of customers periodic payment fees for four years.